TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03918135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: 1000 mg of paracetamol (parol 10mg/ml Mefar, Turkey) intravenous (IV) was given 100 patients~Other Names:~* Perfalgan~* Paracerol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 400mg of ibuprofen(intrafen 400mg/4ml Gen ilaç sanayi, Turkey) intravenous (IV) was given 100 patients~Other Names:~Dorifen
Study: NCT03118752

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Care
Description: The CC intervention will use a novel three-pronged approach to these high-risk patients. Care managers will provide centralized care coordination and specific interventions targeting: (1) the psychiatric disorders, (2) cardiac health behaviors, and (3) the cardiac illness.
Study: NCT04415268

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Surpervised exercise program: Includes a concurrent exercise intervention (strength training and aerobic training), 3 days a week, 60 minutes sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unsupervised exercise
Description: Unsupervised exercise program: The same exercise program learned during the supervised phase will be practiced at home.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFTR Modulators
Description: Standard of care: Lumacaftor with Ivacaftor or Tezacaftor combined with Ivacaftor.~For children between 6 and 11 years of age, Lumacaftor 400 mg combined with Ivacaftor 500 mg in total per day, divided into 2 doses per day; for those over 11 years of age, Tezacaftor 100 mg combined with Ivacaftor 150 mg in the morning, adding a dose of Ivacaftor 150 mg at night.~https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000833-37/ES
Study: NCT03857724

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prolapse surgery
Description: prolapse surgery
Study: NCT04781244

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EndWarts® FREEZE
Description: EndWarts® FREEZE is an alternative home cryotherapy device. Patients don't have to go to the hospital to receive treatment for their wart.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EndWarts® FREEZE
Description: EndWarts® FREEZE is an alternative home cryotherapy device. Patients don't have to go to the hospital to receive treatment for their wart.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Liquid nitrogen
Description: Liquid nitrogen is a conventional cryotherapy treatment for cutaneous wart performed by physician at the hospital.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Liquid nitrogen
Description: Liquid nitrogen is a conventional cryotherapy treatment for cutaneous wart performed by physician at the hospital.
Study: NCT05025033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody, paclitaxel or irinotecan, Apatinib mesylate
Description: PD-1 antibody 200mg intravenous drip every 3 weeks; Apatinib 250mg/day; Chemotherapy: Irinotecan 150mg/m2, intravenous drip every 2 weeks, or Paclitaxel 150mg/m2, intravenous drip, once every 3 weeks.
Study: NCT01112891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 10 ug/day Vitamin D as part of standard pre-natal vitamin supplement, taken from 18 weeks gestation to 6 months postpartum.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 25 ug/day Vitamin D as part of standard pre-natal vitamin supplement, taken from 18 weeks gestation to 6 months postpartum.
Study: NCT01360281

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECR
Description: Resisted exercises
Study: NCT01291433

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pentoxifylline placebo
Description: Placebo for pentoxifylline 400 mg, 1 cp twice a day (7d/7)
Study: NCT00710723

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vitrification
Description: Vitrification using Hemi-straw carrier system.
Study: NCT00561574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmirtazapine
Description: One tablet daily
Study: NCT01433861

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopy-assisted gastrectomy
Description: Laparoscopy-assisted proximal gastrectomy versus Laparoscopy-assisted total gastrectomy
Study: NCT01291433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Pentoxifylline 400 mg: 1 cp twice a day (7d/7)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocopherol acetate
Description: Tocopherol alpha-acetate, 500 mg: 1 capsule twice a day (7d/7)
Study: NCT02675855

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GrafixPRIME®
Description: Human tissue, Wound cover, Application of a non-adherent dressing, a moisture retentive dressing, and a secondary dressing.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dressing Application
Description: Wound cover, Application of a non-adherent dressing, a moisture retentive dressing, and a secondary dressing.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Off-loading (walking boot)
Description: Patients will be fitted for an off-loading device (walking boot) and agree to comply with use of the device during the course of the study

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Off-loading (walking boot)
Description: Patients will be fitted for an off-loading device (walking boot) and agree to comply with use of the device during the course of the study
Study: NCT02288858

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Viviscal Oral Supplement Tablets
Description: Tablet (512 mg)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Viviscal Oral Supplement Tablets
Description: Tablet (512 mg)
Study: NCT01291433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clodronic Acid
Description: Clodronate disodium (clodronic acid) 800 mg: 2 cp per day, 5d/7 (from monday to friday)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tocopherol placebo
Description: Placebo for Tocopherol alpha-acetate, 500 mg: 1 capsule twice a day (7d/7)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clodronate placebo
Description: Placebo for clodronate disodium (clodronic acid) 800 mg: 2 cp per day, 5d/7 (from monday to friday)
Study: NCT01143077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone HCl
Description: Lurasidone tablets, 40 mg/daily, 80 mg/daily, 120 mg/daily for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone HCl
Description: Lurasidone tablets, 40 mg/daily, 80 mg/daily, 120 mg/daily for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone HCl
Description: Lurasidone tablets, 40 mg/daily, 80 mg/daily, 120 mg/daily for 6 weeks
Study: NCT01641861

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Papacarie®
Description: Papacarie® is chemo-mechanical method for caries removal

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional method
Description: caries removal by using rotary instrument.
Study: NCT04214860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APR-246
Description: APR-246 4.5 g/day
Study: NCT00730197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol Sulfate Extended-Release Tablets 8 mg
Description: 8mg, single dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VoSpire® ER Tablets 8 mg
Description: 8mg, single dose fed
Study: NCT04214860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax 400 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Subcutaneous injection, or intravenous infusion
Study: NCT02228603

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high-intensity exercise training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: web-based follow-up program

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: usual care
Study: NCT01767857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xilonix
Description: Xilonix is a True Human Monoclonal Antibody targeting Interleukin 1 alpha, and is administered intravenously every 2 weeks with best supportive care until clinical or radiographic progression.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo plus best supportive care will be administered intravenously every 2 weeks until clinical or radiographic progression.
Study: NCT01421459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2963016
Description: Administered subcutaneously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lantus
Description: Administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OAMs
Description: Administered orally
Study: NCT02325310

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combined measles-mumps-rubella (MMR) vaccine - PRIORIX®
Description: One dose of 0.5 mL vaccine will be administered (intra-muscularly or subcutaneous) in post-partum (before the exit of the maternity) during visit V0. A second dose will be administered at week 8(+/-15 days) during visit V1.
Study: NCT03568084

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MEFAP
Description: multicomponent physical activity program (MEFAP) with 12 weekly sessions of an hour and a half which includes 1) briefing 2) exercises for improving aerobic resistance, muscle strength, proprioception-balance and flexibility and 3) delivery of exercise chart to do at home (two times per week).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control usual practice
Description: Individuals allocated to this arm, will be look after as usual in their health Centers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control usual practice
Description: Individuals allocated to this arm, will be look after as usual in their health Centers.
Study: NCT00160966

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclosporin and Mycophenolate-mofetil
Description: according to the Giessen protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus and Mycophenolate-mofetil
Description: according to Giessen protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus and Mycophenolate-mofetil with change from Mycophenolate-mofetil to Everolimus
Description: according to Giessen protocol
Study: NCT01440062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verum arm receiving Vitamin D oil
Description: oil: 20000 IU/g tablet: 400 IU/g every second day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose arm receiving neutral oil and 400 IU/g of Vitamin D every second day
Description: neutral oil and a low dose of vitamin D
Study: NCT03139318

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: GRID radiotherapy
Description: Patients will be treated with GRID radiotherapy
Study: NCT04243785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTX-A51
Description: Orally administered capsules available in strengths of 0.5 mg, 1.0 mg, 2.0 mg and 7 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTX-A51
Description: Orally administered capsules available in strengths of 0.5 mg, 1.0 mg, 2.0 mg and 7 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTX-A51
Description: Orally administered capsules available in strengths of 0.5 mg, 1.0 mg, 2.0 mg and 7 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine will be administered IV or SC 75 mg/m2 QD on Days 1-7 of each 28-day cycle.
Study: NCT02892123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZW25 (Zanidatamab)
Description: ZW25 administered IV once weekly, once every 2 weeks, or once every 3 weeks. Part 1: in multiple increasing doses; Part 2: ZW25 given at the MTD, OBD, or an RD identified in Part 1; Part 3: ZW25 given at the MTD, OBD, or an RD combined with one of the following selected drug combination:

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Combination therapy with ZW25 - Part 3 Treatment Groups 1 and 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Combination therapy with ZW25 - Part 3 Treatment Groups 2 and 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Combination therapy with ZW25 - Part 3 Treatment Groups 3 and 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: Combination therapy with ZW25 and Capecitabine - Part 3 Treatment Group 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: Combination therapy with ZW25 - Part 3 Treatment Group 8 (may be opened if recommended by the Safety Monitoring Committee and/or the sponsor)
Study: NCT03088215

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: shock-waves
Description: Application of shock-waves (radial and focused)
Study: NCT01858311

Intervention type: DIETARY_SUPPLEMENT
Intervention: Tocotrienol Capsules
Description: Vitamin E TCT capsules- 400mg to 800mg per day (2 in the morning and 2 in the evening)

Intervention type: DIETARY_SUPPLEMENT
Intervention: Tocotrienol Capsules
Description: Vitamin E TCT capsules- 400mg to 800mg per day (2 in the morning and 2 in the evening)

Intervention type: OTHER
Intervention: Placebo Vehicle
Description: Placebo capsules per day (2 in the morning and 2 in the evening)
Study: NCT03488927

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supporting Survivors and Self: An Intervention for Social Supports of Survivors of Partner Abuse and Sexual Aggression (SSS)
Description: The SSS intervention consists of a two-hour session followed by a 90-minute booster session a month following the initial program session. The SSS intervention is delivered in groups of approximately 20 students facilitated by peer educators. The SSS intervention provides participants with specific information on the reasons why positive social reactions are important and negative social reactions can be harmful, examples of what to say and what not to say (including ways to promote healthy coping and discourage unhealthy coping, e.g., drinking to cope), opportunities for roleplay, and an emphasis on the importance of self-care and ways in which self-care can be balanced with the needs of IPV and SA victims.
Study: NCT03654443

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Critical care pain observation tool
Description: The CPOT tool is administered in a crossover manner by two study observers

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Critical care pain observation tool
Description: The CPOT tool is administered in a crossover manner by two study observers
Study: NCT03111966

Intervention type: OTHER
Intervention: Spanish cohort with HCV treated in real practice with Elbasvir/Grazoprevir
Description: Spanish cohort with HCV treated in real practice with Elbasvir/Grazoprevir
Study: NCT01367431

Intervention type: DIETARY_SUPPLEMENT
Intervention: Xanthohumol
Description: PK study with one capsule of one of the three doses randomly assigned

Intervention type: DIETARY_SUPPLEMENT
Intervention: Xanthohumol
Description: PK study with one capsule of one of the three doses randomly assigned

Intervention type: DIETARY_SUPPLEMENT
Intervention: Xanthohumol
Description: PK study with one capsule of one of the three doses randomly assigned
Study: NCT00441454

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transobturator Tension-free vaginal tape (TVT-O)
Description: tension-free vaginal tape (TVT)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Retropubic Tension-free vaginal tape (TVT)
Description: Retropubic Tension-free vaginal tape (TVT)
Study: NCT03857906

Intervention type: DEVICE
Intervention: Intra-Aortic Ballon Pump insertion
Description: The IABP (Ultraflex IAB 7.5F, 2.5mm; Arrow International, Reading, PA) was inserted percutaneously through the right femoral artery in the previous 1 - 6 hours before the scheduled surgery. Positioning of the IABP was guided by radioscopy. The balloon size was based on the patient's height (30, 40 or 50 cc). Transesophageal echocardiography was used to confirm correct IABP placement before and after CABG
Study: NCT01061983

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Activa Deep Brain Stimulation
Description: In DBS, thin wires are used to carry electric current to the parts of the brain involved in OCD symptoms. These wires are implanted surgically and are attached to battery operated stimulators usually implanted in the chest. The study doctor will adjust the settings of the electrical stimulation to optimize treatment for each participant.
Study: NCT03965208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Description: titrated continuous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated heparin
Description: titrated continuous infusion
Study: NCT00412568

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Photorefractive Keratectomy (PRK)
Description: vision correction with PRK
Study: NCT01112891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 50 ug/day Vitamin D as part of standard pre-natal vitamin supplement, taken from 18 weeks gestation to 6 months postpartum.
Study: NCT03787017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC(MP-513 20mg/Metformin XR 1000mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC(MP-513 20mg/Metformin XR 1000mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-513 20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-513 20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR 1000mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR 1000mg
Study: NCT00831350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Subjects will receive study medication ranibizumab 0.5mg. Re-treatment will occur monthly through 6 injections
Study: NCT04400292

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Injection of indocyanine green (ICG)dye
Description: Patients will receive a perilesional injection of indocyanine green (ICG) before the laparoscopic phase of the esophagectomy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near-Infrared Image-Guided
Description: Real-time near-infrared (NIR) fluorescence imaging will be performed by use of the Novadaq PINPOINT minimally invasive system with a laparoscopic camera.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel Lymph Node (SLN) mapping
Description: Any identified SLNs will be dissected during the standard completion lymphadenectomy and esophagectomy.
Study: NCT04139941

Intervention type: DIAGNOSTIC_TEST
Intervention: Test for HCV antibodies with an RDT
Description: Fingerstick whole blood, plasma and serum of each participant is tested with three investigational HCV RDTs and one reference HCV RDT. Plasma is also used for testing with the composite reference standard, HCV viral load and genotyping. All participants are also tested for HIV with an HIV RDT.
Study: NCT01421459

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OAMs
Description: Administered orally
Study: NCT02458391

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care complete decongestive therapy
Description: Participants will receive standard of care complete decongestive therapy consisting of meticulous skin and nail care, manual lymphatic drainage, compression bandaging, remedial exercises and self-care training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care complete decongestive therapy
Description: Participants will receive standard of care complete decongestive therapy consisting of meticulous skin and nail care, manual lymphatic drainage, compression bandaging, remedial exercises and self-care training.
Study: NCT02563249

Intervention type: OTHER
Group type: OTHER
Intervention: Parabolic flight

Intervention type: OTHER
Group type: OTHER
Intervention: movements of the upper limb, the gripping force, muscle activity and eye-cephalic subject movement measurements
Study: NCT01745094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solifenacin
Description: oral
Study: NCT02647515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Study: NCT00851006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Creatine Monohydrate
Description: Creapure brand of creatine monohydrate
Study: NCT00939380

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral intervention sessions
Description: Participants undergo five 60-minute behavioral intervention sessions once or twice weekly for 3 weeks to learn how to engage in effective social and cognitive processing to deal with fears and worries about the transplant and transplant-related concerns.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CD-ROM
Description: Participants receive a laptop computer and a CD-ROM after the first session of behavioral intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DVD and pamphlet
Description: Participants receive a Discovery to Recovery DVD and pamphlet developed by the National Marrow Donor Program (NMDP) describing psychological issues associated with hematopoietic stem cell transplantation (HSCT), the booklet Top Tips for Parent Caregivers During the BMT Process published by National Marrow Donor Program-Link describing caregiver issues during HSCT and advice on how to handle them, 2 walkie-talkies, a laptop to view the DVD.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respite care
Description: Participants receive 5 hours of respite care from a child-life specialist once or twice weekly for 3 weeks.
Study: NCT03160079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: blinatumomab
Description: Cycle 1 Blinatumomab Day 1-7 Continuous IV infusion for 28 days (9 mcg/day) Blinatumomab Day 8-28 Continuous IV infusion for 28 days (28 mcg/day)~Cycle 2-5 Blinatumomab Day 1-28 Continuous IV infusion for 28 days (28 mcg/day)~Cycle length 42 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Cycle 1 Pembrolizumab Day 15 and 36 IV infusion over 30 minutes (200mg)~Cycle 2-5 Pembrolizumab Day 15 and 36 IV infusion over 30 minutes (200mg)
Study: NCT02038452

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depo-Medrone
Description: Steroid Injection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wrist Splint
Description: Simple wrist splint
Study: NCT00642720

Intervention type: DRUG
Group type: OTHER
Intervention: Pegvisomant
Description: if the addition of 40 mg pegvisomant weekly will improve the quality of life of acromegaly patients compared to placebo weekly

Intervention type: DRUG
Group type: OTHER
Intervention: Pegvisomant
Description: if the addition of 40 mg pegvisomant weekly will improve the quality of life of acromegaly patients compared to placebo weekly